Effective Treatment against ESBL-Producing <i>Klebsiella pneumoniae</i> through Synergism of the Photodynamic Activity of Re (I) Compounds with Beta-Lactams

Background: Extended-spectrum beta-lactamase (ESBL) and carbapenemase (KPC<sup>+</sup>) producing <i>Klebsiella pneumoniae</i> are multidrug-resistant bacteria (MDR) with the highest risk to human health. The significant reduction of new antibiotics development can be overcom...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Iván A. González, Annegrett Palavecino, Constanza Núñez, Paulina Dreyse, Felipe Melo-González, Susan M. Bueno, Christian Erick Palavecino
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
Acceso en línea:https://doaj.org/article/a4441cf2c8494ccf9bdf02e9c30745ef
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:a4441cf2c8494ccf9bdf02e9c30745ef
record_format dspace
spelling oai:doaj.org-article:a4441cf2c8494ccf9bdf02e9c30745ef2021-11-25T18:41:30ZEffective Treatment against ESBL-Producing <i>Klebsiella pneumoniae</i> through Synergism of the Photodynamic Activity of Re (I) Compounds with Beta-Lactams10.3390/pharmaceutics131118891999-4923https://doaj.org/article/a4441cf2c8494ccf9bdf02e9c30745ef2021-11-01T00:00:00Zhttps://www.mdpi.com/1999-4923/13/11/1889https://doaj.org/toc/1999-4923Background: Extended-spectrum beta-lactamase (ESBL) and carbapenemase (KPC<sup>+</sup>) producing <i>Klebsiella pneumoniae</i> are multidrug-resistant bacteria (MDR) with the highest risk to human health. The significant reduction of new antibiotics development can be overcome by complementing with alternative therapies, such as antimicrobial photodynamic therapy (aPDI). Through photosensitizer (PS) compounds, aPDI produces local oxidative stress-activated by light (photooxidative stress), nonspecifically killing bacteria. Methodology: Bimetallic Re(I)-based compounds, PSRe-µL1 and PSRe-µL2, were tested in aPDI and compared with a Ru(II)-based PS positive control. The ability of PSRe-µL1 and PSRe-µL2 to inhibit <i>K. pneumoniae</i> was evaluated under a photon flux of 17 µW/cm<sup>2</sup>. In addition, an improved aPDI effect with imipenem on KPC<sup>+</sup> bacteria and a synergistic effect with cefotaxime on ESBL producers of a collection of 118 clinical isolates of <i>K. pneumoniae</i> was determined. Furthermore, trypan blue exclusion assays determined the PS cytotoxicity on mammalian cells. Results: At a minimum dose of 4 µg/mL, both the PSRe-µL1 and PSRe-µL2 significantly inhibited in 3log<sub>10</sub> (>99.9%) the bacterial growth and showed a lethality of 60 and 30 min of light exposure, respectively. Furthermore, they were active on clinical isolates of <i>K. pneumoniae</i> at 3–6 log<sub>10</sub>. Additionally, a remarkably increased effectiveness of aPDI was observed over KPC<sup>+</sup> bacteria when mixed with imipenem, and a synergistic effect from 3 to 6log<sub>10</sub> over ESBL producers of <i>K. pneumoniae</i> clinic isolates when mixed with cefotaxime was determined for both PSs. Furthermore, the compounds show no dark toxicity and low light-dependent toxicity in vitro to mammalian HEp-2 and HEK293 cells. Conclusion: Compounds PSRe-µL1 and PSRe-µL2 produce an effective and synergistic aPDI effect on KPC<sup>+</sup>, ESBL, and clinical isolates of <i>K. pneumoniae</i> and have low cytotoxicity in mammalian cells.Iván A. GonzálezAnnegrett PalavecinoConstanza NúñezPaulina DreyseFelipe Melo-GonzálezSusan M. BuenoChristian Erick PalavecinoMDPI AGarticlephotodynamic therapymulti-drug resistanceantibiotic synergy<i>Klebsiella pneumoniae</i>Pharmacy and materia medicaRS1-441ENPharmaceutics, Vol 13, Iss 1889, p 1889 (2021)
institution DOAJ
collection DOAJ
language EN
topic photodynamic therapy
multi-drug resistance
antibiotic synergy
<i>Klebsiella pneumoniae</i>
Pharmacy and materia medica
RS1-441
spellingShingle photodynamic therapy
multi-drug resistance
antibiotic synergy
<i>Klebsiella pneumoniae</i>
Pharmacy and materia medica
RS1-441
Iván A. González
Annegrett Palavecino
Constanza Núñez
Paulina Dreyse
Felipe Melo-González
Susan M. Bueno
Christian Erick Palavecino
Effective Treatment against ESBL-Producing <i>Klebsiella pneumoniae</i> through Synergism of the Photodynamic Activity of Re (I) Compounds with Beta-Lactams
description Background: Extended-spectrum beta-lactamase (ESBL) and carbapenemase (KPC<sup>+</sup>) producing <i>Klebsiella pneumoniae</i> are multidrug-resistant bacteria (MDR) with the highest risk to human health. The significant reduction of new antibiotics development can be overcome by complementing with alternative therapies, such as antimicrobial photodynamic therapy (aPDI). Through photosensitizer (PS) compounds, aPDI produces local oxidative stress-activated by light (photooxidative stress), nonspecifically killing bacteria. Methodology: Bimetallic Re(I)-based compounds, PSRe-µL1 and PSRe-µL2, were tested in aPDI and compared with a Ru(II)-based PS positive control. The ability of PSRe-µL1 and PSRe-µL2 to inhibit <i>K. pneumoniae</i> was evaluated under a photon flux of 17 µW/cm<sup>2</sup>. In addition, an improved aPDI effect with imipenem on KPC<sup>+</sup> bacteria and a synergistic effect with cefotaxime on ESBL producers of a collection of 118 clinical isolates of <i>K. pneumoniae</i> was determined. Furthermore, trypan blue exclusion assays determined the PS cytotoxicity on mammalian cells. Results: At a minimum dose of 4 µg/mL, both the PSRe-µL1 and PSRe-µL2 significantly inhibited in 3log<sub>10</sub> (>99.9%) the bacterial growth and showed a lethality of 60 and 30 min of light exposure, respectively. Furthermore, they were active on clinical isolates of <i>K. pneumoniae</i> at 3–6 log<sub>10</sub>. Additionally, a remarkably increased effectiveness of aPDI was observed over KPC<sup>+</sup> bacteria when mixed with imipenem, and a synergistic effect from 3 to 6log<sub>10</sub> over ESBL producers of <i>K. pneumoniae</i> clinic isolates when mixed with cefotaxime was determined for both PSs. Furthermore, the compounds show no dark toxicity and low light-dependent toxicity in vitro to mammalian HEp-2 and HEK293 cells. Conclusion: Compounds PSRe-µL1 and PSRe-µL2 produce an effective and synergistic aPDI effect on KPC<sup>+</sup>, ESBL, and clinical isolates of <i>K. pneumoniae</i> and have low cytotoxicity in mammalian cells.
format article
author Iván A. González
Annegrett Palavecino
Constanza Núñez
Paulina Dreyse
Felipe Melo-González
Susan M. Bueno
Christian Erick Palavecino
author_facet Iván A. González
Annegrett Palavecino
Constanza Núñez
Paulina Dreyse
Felipe Melo-González
Susan M. Bueno
Christian Erick Palavecino
author_sort Iván A. González
title Effective Treatment against ESBL-Producing <i>Klebsiella pneumoniae</i> through Synergism of the Photodynamic Activity of Re (I) Compounds with Beta-Lactams
title_short Effective Treatment against ESBL-Producing <i>Klebsiella pneumoniae</i> through Synergism of the Photodynamic Activity of Re (I) Compounds with Beta-Lactams
title_full Effective Treatment against ESBL-Producing <i>Klebsiella pneumoniae</i> through Synergism of the Photodynamic Activity of Re (I) Compounds with Beta-Lactams
title_fullStr Effective Treatment against ESBL-Producing <i>Klebsiella pneumoniae</i> through Synergism of the Photodynamic Activity of Re (I) Compounds with Beta-Lactams
title_full_unstemmed Effective Treatment against ESBL-Producing <i>Klebsiella pneumoniae</i> through Synergism of the Photodynamic Activity of Re (I) Compounds with Beta-Lactams
title_sort effective treatment against esbl-producing <i>klebsiella pneumoniae</i> through synergism of the photodynamic activity of re (i) compounds with beta-lactams
publisher MDPI AG
publishDate 2021
url https://doaj.org/article/a4441cf2c8494ccf9bdf02e9c30745ef
work_keys_str_mv AT ivanagonzalez effectivetreatmentagainstesblproducingiklebsiellapneumoniaeithroughsynergismofthephotodynamicactivityofreicompoundswithbetalactams
AT annegrettpalavecino effectivetreatmentagainstesblproducingiklebsiellapneumoniaeithroughsynergismofthephotodynamicactivityofreicompoundswithbetalactams
AT constanzanunez effectivetreatmentagainstesblproducingiklebsiellapneumoniaeithroughsynergismofthephotodynamicactivityofreicompoundswithbetalactams
AT paulinadreyse effectivetreatmentagainstesblproducingiklebsiellapneumoniaeithroughsynergismofthephotodynamicactivityofreicompoundswithbetalactams
AT felipemelogonzalez effectivetreatmentagainstesblproducingiklebsiellapneumoniaeithroughsynergismofthephotodynamicactivityofreicompoundswithbetalactams
AT susanmbueno effectivetreatmentagainstesblproducingiklebsiellapneumoniaeithroughsynergismofthephotodynamicactivityofreicompoundswithbetalactams
AT christianerickpalavecino effectivetreatmentagainstesblproducingiklebsiellapneumoniaeithroughsynergismofthephotodynamicactivityofreicompoundswithbetalactams
_version_ 1718410791888093184